Pharmaceuticals, Biotechnology and Life Sciences
Shipments for Follow-on Order Under Existing Supply Agreement Will Commence This Quarter STONY BROOK, N.Y.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24apdn&src=ctag" target="_blank"gt;$apdnlt;/agt; lt;a href="https://twitter.com/hashtag/PCR?src=hash"…
Data Supports Continued Dose Escalation and Further Investigation in Metastatic Renal Cell Carcinoma (mRCC) MAINZ, Germany–(BUSINESS WIRE)–EXUMA Biotechnology and affiliate…
Completion of Gene-to-Lead phase for first discovery project targeting METTL3/METTL14 complex NEW YORK & LEIDEN, Netherlands–(BUSINESS WIRE)–Gotham Therapeutics, a biotechnology…
ZURICH–(BUSINESS WIRE)–Regulatory News: Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has…
SAN FRANCISCO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/EHA24?src=hash" target="_blank"gt;#EHA24lt;/agt;–Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, today announced that…
– Vofatamab activates immune changes in immunologically cold tumors and in combination increases patient response rates – – Data from…
PharmaCyte Biotech Proceeding with GMP Production of Pancreatic Cancer Product After Successful Changes to Manufacturing Process
The KEYTRUDA breast cancer clinical development program encompassesseveral internal and external collaborative studies, including threeongoing registration-enabling studies in TNBC.
Quality-adjusted progression free survival (QA-PFS) andquality-adjusted time without cancer related symptoms or toxicity(Q-TWiST) demonstrate the benefit of Rubraca maintenance treatment overplacebo from a patient perspective
OTX-TP failed to meet primary endpoint but achieved statisticallysignificant reduction of intraocular pressure versus placebo at eight ofthe nine pre-specified time points